Table 4 OS on specific treatments, comparison by race.
From: The impact of race on survival in metastatic prostate cancer: a systematic literature review
Study | Populationa | Type of Analysis/Results | Specific Treatment | Whiteb | Black | Asian |
|---|---|---|---|---|---|---|
HR (95% CI), p value | ||||||
Sartor (2020) [32] | mCRPC | Multivariable, PSA matched cohort | Sipuleucel-T | Reference | 0.6 (0.48–0.74), p < 0.001 | NR |
Marar (2022) [29] | mCRPC | Propensity score–based inverse probability of treatment weighting | Abiraterone | Reference | 0.76 (0.60–0.98), p=NR | NR |
Enzalutamide | Reference | 0.87 (0.66–1.14), p=NR | NR | |||
Tutrone (2019) [80] | mCRPC Baseline PSA < 5 | Univariable | Sipuleucel-T | Reference | 0.49 (0.26–0.92), p = 0.026 | NR |
mCRPC Baseline PSA ≥ 5 | Univariable | Sipuleucel-T | Reference | 0.80 (0.66–0.97), p = 0.024 | NR | |
Ramalingam (2017) [63] | mCRPC | Multivariable | Abiraterone Acetate | Reference | 0.678 (0.356–1.290), p = 0.2363 | NR |
Zhao (2020) [39] | mCRPC | Multivariable | 222Radium | Referencec | 0.75 (0.57–0.99), p = 0.045 | NR |
Hawley (2022) [64] | mCRPC | Log rank | Sipuleucel-T | Reference | p = 0.07 | NR |
George (2021) [46] | mCRPC | Multivariable | Enzalutamide or Abiraterone | Reference | 0.67 (0.592–0.758), p < 0.0001 | NR |
Muralidhar (2020) [77] | mCRPC | Multivariable | Sipuleucel-T | Reference | 0.542 (0.371–0.792), p = 0.002 | NR |
Leuva (2019) [65] | mCRPC | Univariable | Enzalutamide or Abiraterone | Reference | p = 0.02d | NR |
Ng (2021) [62] | mCRPC | Log-rank test | Enzalutamide | Reference | p = 0.91 | NR |
Zhang (2020) [73] | mCRPC | Unclear | Sipuleucel-T | Reference | NR | 0.69 (0.4–1.4), p = 0.2777 |
